niacinamide has been researched along with abt-199 in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 3 (75.00) | 2.80 |
Authors | Studies |
---|---|
Arribas, AJ; Bertoni, F; Cascione, L; Curti, E; Gaudio, E; Priebe, V; Rossi, D; Spriano, F; Stathis, A; Tarantelli, C; Zhang, L; Zucca, E | 1 |
Abbott, D; Amaya, M; Becker, MW; Culp-Hill, R; D'Alessandro, A; DeGregori, J; Gamboni, F; Gehrke, S; Gustafson, A; Inguva, A; Jones, CL; Jordan, CT; Krug, A; Minhajuddin, M; Nemkov, T; Pei, S; Pollyea, DA; Reisz, JA; Smith, CA; Stevens, BM; Winters, A; Ye, H | 1 |
Majeti, R; Zhang, TY | 1 |
Ai, H; Chen, L; Ji, X; Mi, RH; Song, YP; Wei, XD; Yin, QS | 1 |
4 other study(ies) available for niacinamide and abt-199
Article | Year |
---|---|
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Synergism; Humans; Hydrazines; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Niacinamide; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Triazoles; Tumor Cells, Cultured | 2019 |
Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Niacinamide; Stem Cells; Sulfonamides | 2020 |
Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Niacinamide; Sulfonamides | 2020 |
[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2022 |